SuperworthMetaVia EPS MTVA
Diluted earnings per share by quarter and over the last twelve months, from 2015.
- Last 12 months, to Jun 30, 2026
- −$4.08
- Latest quarter, Q2 FY26
- −$0.90
- Fiscal year 2025
- −$9.19
MetaVia's earnings per share was −$4.08 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.90.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$9.19 | n/a |
| FY2024 | −$46.53 | n/a |
| FY2023 | −$26.95 | n/a |
| FY2022 | −$975.04 | n/a |
| FY2021 | −$1738.88 | n/a |
| FY2020 | −$4831.20 | n/a |
| FY2019 | −$10612.80 | n/a |
| FY2018 | −$114840.00 | n/a |
| FY2017 | −$213180.00 | −234% |
| FY2016 | $159060.00 | n/a |
| FY2015 | −$322080.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.90 | n/a | −$4.08 | |
| Q1 FY26 | −$0.79 | n/a | −$6.05 | |
| Q4 FY25 | −$0.85 | n/a | −$9.19 | |
| Q3 FY25 | −$1.54 | n/a | −$13.95 | |
| Q2 FY25 | −$2.87 | n/a | −$18.46 | |
| Q1 FY25 | −$3.93 | n/a | −$35.94 | |
| Q4 FY24 | −$5.61 | n/a | −$46.53 | |
| Q3 FY24 | −$6.05 | n/a | −$52.36 | |
| Q2 FY24 | −$20.35 | n/a | −$54.56 | |
| Q1 FY24 | −$14.52 | n/a | −$35.86 | |
| Q4 FY23 | −$11.44 | n/a | −$26.95 | |
| Q3 FY23 | −$8.25 | n/a | −$70.07 |
Against its peers
Companies in Drug Manufacturers - General nearest MetaVia's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MTVAMetaVia | −$4.08 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on MetaVia
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.